Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine

Human neonatal rotavirus vaccine (RV3-BB) targets rotavirus from birth

BACKGROUND A strategy of administering a neonatal rotavirus vaccine at birth to target early prevention of rotavirus gastroenteritis may address some of the barriers to global implementation of a rotavirus vaccine. METHODS We conducted a randomized, double-blind, placebo-controlled trial in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) in preventing r...

Divergent immunomodulating effects of probiotics on T cell responses to oral attenuated human rotavirus vaccine and virulent human rotavirus infection in a neonatal gnotobiotic piglet disease model.

Rotaviruses (RVs) are a leading cause of childhood diarrhea. Current oral vaccines are not effective in impoverished countries where the vaccine is needed most. Therefore, alternative affordable strategies are urgently needed. Probiotics can alleviate diarrhea in children and enhance specific systemic and mucosal Ab responses, but the T cell responses are undefined. In this study, we elucidated...

Neonatal Gnotobiotic Piglet Disease Model Virulent Human Rotavirus Infection in a Attenuated Human Rotavirus Vaccine and Probiotics on T Cell Responses to Oral Divergent Immunomodulating Effects of

Rotavirus vaccine--time to act.

Rotavirus vaccines are finally available, and introducing them into the routine vaccination schedule will have a significant impact on the health of children fter a dramatic false start, oral rotavirus vaccines are now available to prevent severe, dehydrating diarrhoea in small children. Rotavirus infection in children can be as severe as cholera in adults, but affects a group who cannot compla...

Rotarix (RIX4414): an oral human rotavirus vaccine.

Rotavirus is the most common cause of severe gastroenteritis in children younger than 3 years of age worldwide. New rotavirus vaccine candidates were required to confer early protection against the most common rotavirus serotypes and to be well tolerated and not associated with intussusception. RIX4414 is a human-attenuated G1(P8) oral rotavirus vaccine administered in two doses at approximatel...